The Systemic Consequences of STAT3 Dysregulation in Long COVID:

A Unifying Molecular Pathway Across Malignancy, Autoimmunity, and Immune Dysregulation

Dr Graham Exelby June 2025

Abstract:

Long COVID is increasingly recognized as a condition marked by chronic immune activation, with the Signal Transducer and Activator of Transcription 3 (STAT3) emerging as a central node in its pathophysiology. STAT3 activation is sustained through persistent cytokine signalling, particularly via the IL-6–JAK pathway, and intersects with inflammatory pathways including TLR4, RAGE, and CCL2.

This paper outlines the clinical consequences of persistent STAT3 dysregulation, linking it to elevated risks for malignancies, autoimmune diseases, immunodeficiency, and allergic conditions. The molecular intersections of STAT3 with IL-6, IL-23, and PD-1/PD-L1 signalling underscore its pivotal role in mediating immune pathology. We explore these pathways in detail and highlight therapeutic strategies targeting STAT3-related axes, including the use of telmisartan, nicotinamide riboside, lymphatic therapy, and immune modulators.

Introduction

Long COVID, also known as Post-Acute Sequelae of COVID-19 (PASC), affects a significant proportion of individuals recovering from SARS-CoV-2 infection, with symptoms persisting for months or years. These include fatigue, cognitive impairment ("brain fog"), and organ dysfunction, posing a substantial public health burden (Douaud et al., 2022). The underlying mechanisms are complex, but chronic inflammation is increasingly recognized as a central driver (Deeks et al., 2022).

Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor (proteins that regulate gene expression by controlling the transcription of DNA into RNA, critical for regulating immune responses, including inflammation, cell survival, and immune cell function (Rezaei et al., 2021). In acute COVID-19, STAT3 hyperactivation contributes to cytokine storms, hyper-inflammation, lung fibrosis, thrombosis, and immune dysfunction (Rezaei et al., 2021). Given its role in inflammatory signalling, STAT3 may also sustain chronic inflammation in Long COVID, particularly through interactions with pathways such as RAGE (Receptor for Advanced Glycation End-products), TLR4 (Toll-Like Receptor 4), CCL2 (Chemokine Ligand 2), and NK (Natural Killer) cell dysfunction.

STAT3 Activation in Acute COVID-19

STAT3 is activated by cytokines such as IL-6, which phosphorylate STAT3 via the JAK (Janus Kinase) pathway, leading to dimerization and nuclear translocation (Rezaei et al., 2021). In acute COVID-19, STAT3 hyperactivation is implicated in several pathological processes:

• Hyper-inflammation: STAT3 upregulates pro-inflammatory cytokines (e.g., IL-6, TNF-α) and chemokines, amplifying the cytokine storm (Rezaei et al., 2021).

• Lung Fibrosis and Thrombosis: STAT3 promotes fibroblast proliferation and coagulation, contributing to lung damage and thromboembolic events (Rezaei et al., 2021).

• Immune Dysfunction: STAT3 activation is associated with lymphopenia and impaired anti-viral immune responses, exacerbating disease severity (Rezaei et al., 2021).

These mechanisms, well-documented in acute COVID-19, provide a foundation for understanding STAT3’s potential role in Long COVID.

Role of STAT3 Activation in Long COVID:

In Long COVID, sustained IL-6 levels, RAGE activation, and TLR4 feedback loops may lead to chronic STAT3 phosphorylation, resulting in systemic consequences across multiple organ systems.  Recent studies using single-cell transcriptomics and post-mortem histopathology have demonstrated sustained STAT3 phosphorylation in monocytes, endothelial cells, and astroglial cells in affected individuals.

Persistent IL-6 and CCL2 signalling, combined with DAMP-induced TLR4 and RAGE activation, leads to a feedforward loop maintaining STAT3-driven inflammation.  New findings also implicate STAT3 in glymphatic dysfunction through astrocyte activation, linking it to neuroinflammation and cognitive impairment.

Moreover, STAT3 appears to interfere with mitochondrial recovery, inhibits mitophagy, and suppresses NAD+/SIRT3 signalling, potentially explaining the post-exertional malaise and metabolic exhaustion seen in Long COVID patients. This reinforces STAT3 not just as a marker, but as a potential master regulator in post-viral syndromes. (Deeks et al., 2022). (Douaud et al., 2022).( Wu et al., 2021). (Maucourant et al., 2021).

STAT3 and Malignancy

Persistent STAT3 activation promotes oncogenesis by enhancing proliferation, survival, angiogenesis, and immune evasion. In haematological cancers such as leukemia and lymphoma, constitutive STAT3 signalling maintains malignant cell viability. In solid tumours like breast, lung, and liver cancers, STAT3 is linked to chronic inflammation and PD-L1 upregulation, enabling tumour escape from immune surveillance.

Autoimmune Diseases

STAT3 is implicated in autoimmune diseases through its promotion of Th17 differentiation and B-cell survival:

• SLE: Hyperactive STAT3 drives autoantibody production and nephritis.

• RA: IL-6–STAT3 activation in synoviocytes promotes joint destruction.

• MS: IL-23–STAT3–RORγt axis supports pathogenic Th17 expansion.

• IBD: STAT3 in T cells and ILCs mediates IL-17 and IL-22 production.

• Seronegative arthritis may involve both STAT3 and TLR4 pathways, particularly through microbial antigen stimulation and innate immune priming.

Immunodeficiency Syndromes

Loss-of-function STAT3 mutations cause Hyper-IgE Syndrome (HIES), with defective Th17 immunity and increased infection susceptibility. Conversely, gain-of-function STAT3 mutations lead to early-onset autoimmunity, lymphoproliferation, and immune exhaustion, mimicking patterns seen in Long COVID.

Allergic Diseases

STAT3 is required for mast cell degranulation and IgE signalling. Hyperactivation may amplify allergic responses, potentially contributing to food allergies and mast cell activation symptoms observed in post-viral states.

Molecular Pathways

• IL-6–JAK–STAT3: Central in sustaining inflammation and fibrosis.

• IL-23–STAT3–RORγt: Drives Th17 responses in IBD and CNS autoimmunity.

• PD-1/PD-L1–STAT3: Enables immune evasion and suppresses antiviral responses.

• TLR4/RAGE–STAT3 Loop: Propagates innate-adaptive immune crosstalk in chronic inflammation.

  
  

Therapeutic Implications

Although direct STAT3 inhibitors are not widely available clinically, indirect strategies include:

• Telmisartan (PPAR-γ activation, RAGE suppression) (Yamagishi et al 2008 )

• Nicotinamide Riboside + Magnesium (NAD+ restoration, SIRT activation)

• Lymphatic Therapy (clearance of DAMPs, S100 proteins)

• Low-Dose Naltrexone (microglial and TLR4 modulation)

• Hyperbaric Oxygen (anti-hypoxic, anti-inflammatory effects)

  
  

Conclusion

Persistent STAT3 activation in Long COVID creates a fertile ground for malignancy, autoimmunity, immune deficiency, and allergy. It serves as a unifying mechanistic link in post-viral syndromes and offers multiple therapeutic targets. Future studies must evaluate whether monitoring and modulating STAT3 activity can prevent the long-term complications associated with chronic post-viral inflammation.

References

1.     Chiappalupi, S. et al. (2021). Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure. Frontiers in Immunology, 12, 637542.

2.     Deeks, S.G. et al. (2022). Long COVID (PASC) maintained by TLR4/RAGE-loop. International Journal of Molecular Sciences, 2(3), 33.

3.     Douaud, G. et al. (2022). SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature, 604(7907), 694–700.

4.     Huang, C. et al. (2020). Unique immunological profile in patients with COVID-19. Cell, 182(1), 8–20.

5.     Kaur, J. et al. (2021). Hyperactivated RAGE in comorbidities as a risk factor for severe COVID-19—The Role of RAGE-RAS Crosstalk. International Journal of Molecular Sciences, 22(12), 6494.

6.     Liu, Y. et al. (2023). RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity. Nature Immunology, 24(1), 105–115.

7.     Maucourant, C. et al. (2021). NK cell dysfunction in patients with COVID-19. Nature Immunology, 22(10), 1252–1261.

8.     Rezaei, N. et al. (2021). Contribution of STAT3 to the pathogenesis of COVID-19. Journal of Medical Virology, 93(5), 2759–2767.

9.     Wu, H. et al. (2021). Activation of STAT3 signaling in kidney of COVID-19 patients. Infection, 49(6), 1231–1239.

10.  Jones, S.A. et al. (2011). IL-6 signaling pathways in inflammatory diseases. The Journal of Clinical Investigation, 121(9), 3375–3383.

11.  Smith, K.A. (2018). STAT3 activation in human diseases. Clinical Immunology, 192, 12–17.

12.  O'Shea, J.J. et al. (2013). The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annual Review of Medicine, 64, 311–328.

13.  Durant, L. et al. (2010). Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity, 32(5), 605–615.

14.  Zhu, J. et al. (2010). Differentiation of effector CD4 T cell populations. Annual Review of Immunology, 28, 445–489.

15.  Lovato, P. et al. (2011). STAT3 activation contributes to Th17 cell induction and skin inflammation in human psoriasis. Journal of Investigative Dermatology, 131(7), 1339–1348.

16.  Yang, L., Xie, X., Tu, Z. et al. The signal pathways and treatment of cytokine storm in COVID-19. Sig Transduct Target Ther 6, 255 (2021). https://doi.org/10.1038/s41392-021-00679-0

17.  Ahuja A, Kim E, Sung GH, Cho JY. STAT3 Differentially Regulates TLR4-Mediated Inflammatory Responses in Early or Late Phases. Int J Mol Sci. 2020;21(20):7675. Published 2020 Oct 16. doi:10.3390/ijms21207675

18.  Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. S100 Proteins As an Important Regulator of Macrophage Inflammation. Front Immunol. 2018 Jan 5;8:1908. doi: 10.3389/fimmu.2017.01908. PMID: 29379499; PMCID: PMC5770888.

19.  Bu LL, Yu GT, Wu L, et al. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. J Dent Res. 2017;96(9):1027-1034. doi:10.1177/0022034517712435

20.  Suzanne Ostrand-Rosenberg, Lucas A. Horn, Samuel T. Haile; The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity. J Immunol 15 October 2014; 193 (8): 3835–3841. https://doi.org/10.4049/jimmunol.1401572

21.  Chen WY, Chen H, Hamada K, et al. Transcriptomics identifies STAT3 as a key regulator of hippocampal gene expression and anhedonia during withdrawal from chronic alcohol exposure. Transl Psychiatry. 2021;11(1):298. Published 2021 May 20. doi:10.1038/s41398-021-01421-8

22.  Li M, Plecitá-Hlavatá L, Dobrinskikh E, McKeon BA, Gandjeva A, Riddle S, Laux A, Prasad RR, Kumar S, Tuder RM, Zhang H, Hu CJ, Stenmark KR. SIRT3 Is a Critical Regulator of Mitochondrial Function of Fibroblasts in Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2023 Nov;69(5):570-583. doi: 10.1165/rcmb.2022-0360OC. PMID: 37343939; PMCID: PMC10633840.

23.  Miyamoto T, Mori T, Yoshimura A, Toyama T. STAT3 is critical to promote inflammatory cytokines and RANKL expression in inflammatory arthritis. Arthritis Res Ther. 2012;14(Suppl 1):P43. doi:10.1186/ar3644

24.  Erlich TH, Yagil Z, Kay G, Peretz A, Migalovich-Sheikhet H, Tshori S, Nechushtan H, Levi-Schaffer F, Saada A, Razin E. Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis. J Allergy Clin Immunol. 2014 Aug;134(2):460-9. doi: 10.1016/j.jaci.2013.12.1075. Epub 2014 Feb 28. PMID: 24582310.

25.  Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation. Protein Pept Lett. 2008;15(8):850-3. doi: 10.2174/092986608785203746. PMID: 1885575